glycoprotein IIb/IIIa inhibitor

Fasting Glucose, NT-proBNP, Treatment with Eptifibatide, and Outcomes in Non–ST-Segment Elevation Acute Coronary Syndromes: An Analysis from EARLY ACS

January 12, 2017

Serdar Farhan, Robert M. Clare, Rudolf Jarai, Robert P. Giugliano, Yuliya Lokhnygina, Robert A. Harrington, L. Kristin Newby, 1, Kurt Huber. Fasting Glucose, NT-proBNP, Treatment with Eptifibatide, and Outcomes in Non–ST-Segment Elevation Acute Coronary Syndromes: An Analysis from EARLY ACS. International Journal of Cardiology (2017). Author Affiliations a. 3rd Department of Internal Medicine, Cardiology, and […]

Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions

October 30, 2015

Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa inhibitor Abciximab for Saphenous Vein Graft Interventions, 30 oct, 2015, Cardiovascular Revascularization Medicine, Ralf E. Harskamp, Niels Hoedemaker, L. Kristin Newby, Pier Woudstra, Maik J. Grundeken, Marcel A. Beijk, Jan J. Piek, Jan G. Tijssen, Rajendra H. Mehta, Robbert J. de Winter Academic Medical Center – University of Amsterdam, Amsterdam, The Netherlands,VU University Medical Center, […]